Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of 2013/2014 bioCSL trivalent inactivated influenza vaccine in healthy adults
2013-001420-19Phase 4Completed
- Sponsor
- CSL Seqirus
- Start
- Apr 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Afluria in influenza, sponsored by CSL Seqirus. Primary endpoint: Seroconversion or significant increase in antibody titre. Started Apr 2013; status: completed.
02
Drugs
Afluria
03
Conditions
influenza
Beyond the preview
Go deeper on 2013-001420-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001420-19.